---
title: "Reducing Risk, Enhancing Flexibility: Lonza’s Approach to Custom Media Manufacturing"
description: This webinar explores Lonza's state-of-the-art custom cell culture media manufacturing capabilities in the USA and Europe.
---

[![BPI Media_Logo 2_Color 1](https://bpi.bioprocessintl.com/hs-fs/hubfs/BPI%20Media_Logo%202_Color%201.png?width=350&height=161&name=BPI%20Media_Logo%202_Color%201.png)](https://bioprocessintl.com/)

# ![ATE-Logo-2024-1](https://bpi.bioprocessintl.com/hs-fs/hubfs/ATE-Logo-2024-1.png?width=590&height=204&name=ATE-Logo-2024-1.png)

# Reducing Risk, Enhancing Flexibility:

# Lonza’s Approach to Custom Media Manufacturing

|  |
| --- |

## Presenters:

****![11-20-2025-Lonza-ATE-Speaker-HS-Cropped](https://bpi.bioprocessintl.com/hs-fs/hubfs/11-20-2025-Lonza-ATE-Speaker-HS-Cropped.png?width=150&height=223&name=11-20-2025-Lonza-ATE-Speaker-HS-Cropped.png)****

**Vipul Saxena **

*Subject Matter Expert,*

*Global Media Solutions,*

Lonza Biosciences

 

Vipul Saxena is a seasoned biopharma professional with over a decade of expertise in upstream cell culture media and process development. As subject matter expert, global media solutions at Lonza Biosciences, he leads technical excellence and business strategy across India and the Middle East, supporting media solutions for protein therapeutics, vaccines, and cell & gene therapy.

Vipul brings end-to-end comprehension and proven expertise of upstream cell culture within CDMO and product based environments, serving as the key technical interface for clients, auditors and production teams. His experience spans process development, consistency, scale-up/scale-down, technology transfer, and biologics manufacturing. Prior to joining Lonza, he worked as an R&D scientist at Dr. Reddy’s Laboratories and Stelis Biopharma, where he led the development of antibody, enzymes, and vaccine-based therapeutics. His efforts played a key role in advancing scalable bioprocessing strategies and achieving regulatory milestones. In addition, Vipul has transitioned R&D products to market, including regulatory approvals for human use. Outside of work, Vipul enjoys trekking, photography, traveling, and is an avid movie buff.

## About this event:

#### Date: November 20, 2025

#### Times:

- #### 11 am EST | 8 am PST
- #### 11 am CET | 5 am EST

#### Duration: 30 minutes

Scaling biologics programs comes with complex media manufacturing decisions from maintaining intellectual property protection to ensuring consistent quality across global production sites. Many biomanufacturers face challenges such as limited internal capacity, vendor reliability concerns, and lack of flexibility from traditional suppliers.

In this webinar, Vipul Saxena, Lonza's SME for cell culture media will share how custom media manufacturing can address these barriers through GMP-compliance, scalable production, reliable global supply, and decades of expertise. He will present case studies to demonstrate seamless media transitions, mitigated manufacturing risks, and accelerated time-to-market.

Key takeaways:

- Minimize risk with stable supply chains and GMP-compliance.
- Scalable solutions for accelerated time-to-market.
- Flexible options from an experienced provider.

-  

-  

©2015 BioProcess International All Rights reserved